Q1 26 EPS
$-0.13
BEAT +35.36%
Est. $-0.20
Q1 26 Revenue
$348.1M
BEAT +0.78%
Est. $345.4M
vs S&P Since Q1 26
+1.5%
BEATING MARKET
TEM +0.8% vs S&P -0.7%
Market Reaction
Did TEM Beat Earnings? Q1 2026 Results
Tempus AI delivered a notably strong first quarter for fiscal 2026, with revenue of $348.12 million growing 36.1% year-over-year and edging past the $345.44 million consensus estimate, while a non-GAAP loss of $0.13 per share came in well ahead of th… Read more Tempus AI delivered a notably strong first quarter for fiscal 2026, with revenue of $348.12 million growing 36.1% year-over-year and edging past the $345.44 million consensus estimate, while a non-GAAP loss of $0.13 per share came in well ahead of the $0.20 consensus by 35.36%, reflecting meaningful operational progress. The primary engine behind the beat was broad-based momentum across both segments, with Diagnostics generating $261.10 million on 34.7% growth and Data and Applications contributing $87.02 million on 40.5% growth, the latter driven largely by surging biopharma demand for data licensing and AI modeling services. Gross margin expanded to 63.8% from 60.7% a year ago, and Adjusted EBITDA narrowed to a loss of just $2.83 million versus negative $16.17 million in the prior-year period. TEM's recent momentum continued into the outlook, as management raised full-year 2026 revenue guidance to $1.59 to $1.60 billion while reaffirming approximately $65 million in full-year Adjusted EBITDA.
Key Takeaways
- • Oncology diagnostic volume growth of 28% year-over-year
- • Hereditary volume growth of 54% (7% adjusted for Ambry pre-acquisition volumes)
- • MRD volume of approximately 6,500 tests, up ~500% year-over-year
- • Insights (data licensing and modeling) revenue growth of 44.1% year-over-year
- • Gross margin expansion to 63.8% from 60.7% year-over-year
TEM Forward Guidance & Outlook
Tempus raised full-year 2026 revenue guidance to $1.59 billion–$1.60 billion, representing approximately 25% annual growth, up from prior guidance. The company continues to expect full-year 2026 Adjusted EBITDA of approximately $65 million.
TEM YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
TEM Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense value of our multimodal data and corresponding AI models.”
— Eric Lefkofsky, Q1 2026 Earnings Press Release
TEM Earnings Trends
TEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TEM EPS Trend
Earnings per share: estimate vs actual
TEM Revenue Trend
Quarterly revenue: estimate vs actual
TEM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.20 | $-0.13 | +35.36% | $348.1M | +0.78% |
| Q4 25 BEAT FY | $-0.05 | $-0.04 | +22.03% | $367.2M | +1.05% |
| FY Full Year | — | $-0.61 | — | $1.27B | — |
| Q3 25 BEAT | $-0.18 | $-0.11 | +37.25% | $334.2M | +1.68% |
| Q2 25 BEAT | $-0.25 | $-0.25 | +1.15% | $314.6M | +5.67% |
| Q1 25 BEAT | $-0.27 | $-0.24 | +10.21% | $255.7M | +3.07% |